Presentation is loading. Please wait.

Presentation is loading. Please wait.

Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. Curcumin enhances effects of bortezomib to inhibit angiogenesis.

Published byMaximilian Carpenter Modified over 5 years ago

Similar presentations

Presentation on theme: "Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. Curcumin enhances effects of bortezomib to inhibit angiogenesis."— Presentation transcript:

1 Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples.
Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. A, left, immunohistochemical analysis of the microvessel density marker CD31 in multiple myeloma tumor samples. Samples from three animals in each treatment group were analyzed. Representative data. A, right, quantification of CD31+ microvessel density as described in Materials and Methods. Mean ± SE of triplicate. B, left, immunohistochemical analysis of VEGF in multiple myeloma tumor samples revealed that curcumin alone and in combination with bortezomib suppresses angiogenesis. Samples from three animals in each treatment group were analyzed. Representative data. B, right, quantification of VEGF as described in Materials and Methods. Mean ± SE of triplicate. Bokyung Sung et al. Mol Cancer Ther 2009;8: ©2009 by American Association for Cancer Research

Download ppt "Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. Curcumin enhances effects of bortezomib to inhibit angiogenesis."

Similar presentations

DNA content flow cytometric histograms of propidium iodide–stained A549 cells. DNA content flow cytometric histograms of propidium iodide–stained A549.

DNA content flow cytometric histograms of propidium iodide–stained A549 cells. DNA content flow cytometric histograms of propidium iodide–stained A549.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.

Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.
Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs
PARPi combinations against HR-proficient tumors.

PARPi combinations against HR-proficient tumors.
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
ROS induction and ATR inhibition synergize in inducing multiple myeloma (MM) cell death. ROS induction and ATR inhibition synergize in inducing multiple.

ROS induction and ATR inhibition synergize in inducing multiple myeloma (MM) cell death. ROS induction and ATR inhibition synergize in inducing multiple.
Regorafenib inhibits angiogenesis and induces apoptosis.

Regorafenib inhibits angiogenesis and induces apoptosis.
Expression of p110γ isoform in macrophages promotes tumor growth and angiogenesis. Expression of p110γ isoform in macrophages promotes tumor growth and.

Expression of p110γ isoform in macrophages promotes tumor growth and angiogenesis. Expression of p110γ isoform in macrophages promotes tumor growth and.
Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.
Antitumor activity of bevacizumab in PDX models was not correlated with the ratio of human and mouse VEGF-A of the models. Antitumor activity of bevacizumab.

Antitumor activity of bevacizumab in PDX models was not correlated with the ratio of human and mouse VEGF-A of the models. Antitumor activity of bevacizumab.
Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.

Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.
Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.

Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.
TFAP2A knockdown inhibits tumor growth in vivo.

TFAP2A knockdown inhibits tumor growth in vivo.
Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.

Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.
Coinjection of CAFs induces a collagen cross-link switch in tumor stroma. Coinjection of CAFs induces a collagen cross-link switch in tumor stroma. A,

Coinjection of CAFs induces a collagen cross-link switch in tumor stroma. Coinjection of CAFs induces a collagen cross-link switch in tumor stroma. A,
Effect of HA on hematopoietic recovery in tumor-bearing mice.

Effect of HA on hematopoietic recovery in tumor-bearing mice.
Identification of NSC as a FADD-kinase inhibitor.

Identification of NSC as a FADD-kinase inhibitor.
PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Similar presentations

Ads by Google